Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp (UTHR) reported insider activity by Chairperson & CEO Martine A. Rothblatt involving option exercises and related sales executed through family trusts. A family trust exercised 9,500 stock options at an exercise price of $135.42 per share, converting them into 9,500 shares of common stock held indirectly.
On the same date, the trust sold a total of 9,500 common shares in multiple open-market transactions at weighted average prices ranging from about $501.06 to $508.17 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Following the derivative transaction, a family trust continues to hold 122,910 stock options, while reported common stock holdings include 40,513 shares held directly by Rothblatt and 166 shares held indirectly by a spouse, plus additional indirect trust holdings.
UNITED THERAPEUTICS Corp’s Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock, then sold 9,500 shares on August 14, 2026 in multiple open‑market trades at weighted‑average prices between about $494.61 and $501.14. The filing reports 132,410 stock options remaining in a family trust after this exercise, and direct holdings of 40,513 common shares plus 166 shares held indirectly by a spouse. These transactions were made under a pre‑arranged 10b5-1 trading plan adopted November 7, 2025, which continues until either the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026.
UNITED THERAPEUTICS Chairperson & CEO Martine A. Rothblatt reported an option exercise and related stock sales for family trusts. On 2026-08-13, a family trust exercised 9,500 stock options at an exercise price of $135.42 per share, receiving 9,500 shares of common stock indirectly. The trust then sold 9,500 shares in multiple trades at weighted-average prices generally around $500–$513 per share. Following the option exercise, the trust continues to hold 141,910 stock options expiring on March 15, 2027. Separately, Rothblatt holds 40,513 shares directly and 166 shares indirectly through a spouse. The option exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 options expiring March 15, 2027 or December 31, 2026.
United Therapeutics Corporation has an updated ownership report from Martine A. Rothblatt on its common stock. Rothblatt reports beneficial ownership of 2,333,721 shares of common stock, representing 5.3% of the class.
The holdings include 843,023 shares over which Rothblatt has sole voting and dispositive power and 1,490,698 shares over which voting and dispositive power is shared. The position includes currently exercisable options held directly and through a family trust, as well as shares held through various trusts, a spouse, and charitable organizations where Rothblatt or related parties have differing levels of investment and voting power.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 and acquired an equal number of common shares on 2026-08-12. The trust then sold 9,500 common shares in multiple trades at weighted-average prices around $507–$521 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. After the option exercise, the family trust held 151,410 stock options with a March 15, 2027 expiration, while Rothblatt also reported 40,513 directly held common shares and 166 shares held indirectly by a spouse.
United Therapeutics Corporation has a significant shareholder disclosure from Wellington Management Group LLP and related entities. These Wellington entities report 1,379,025 shares of United Therapeutics common stock as beneficially owned, representing 3.25% of the outstanding class. The shares are held of record by clients of various Wellington investment advisers, with Wellington acting as a parent holding company and controller of those advisers.
The Wellington entities report no sole voting or dispositive power over the shares. They report shared voting power over 1,328,525 shares and shared dispositive power over 1,379,025 shares. Ownership is below five percent of the class, and no individual client is known to have rights over more than five percent of the shares.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share into common stock on 2026-08-11, then sold 9,500 common shares in multiple trades at prices reported between roughly $512.94 and $531.29 per share. The option exercise and related sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 stock options expiring March 15, 2027 and is scheduled to continue until the earlier of that full exercise or December 31, 2026. Following the option transaction, a family trust associated with the reporting person held 160,910 stock options, and reported direct common stock holdings were 40,513 shares, with an additional 166 shares held indirectly by spouse and further shares held in various family trusts.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share on August 10, 2026, acquiring 9,500 shares of common stock. On the same date, those 9,500 common shares were sold in multiple open-market transactions at prices generally in the $523–$539 per-share range. Following the option exercise, the trust continues to hold 170,410 stock options with an expiration date of March 15, 2027. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Separately, Rothblatt reports direct ownership of 40,513 common shares and indirect ownership of 166 common shares held by a spouse, with additional indirect holdings in family trusts.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options into common stock at an exercise price of $135.42 per share and on August 7, 2026 sold 9,500 common shares in multiple transactions at per-share prices reported between roughly $525 and $540. The options transaction left 179,910 stock options held by the trust. These trades were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Reported holdings also include 40,513 shares held directly and 166 shares held indirectly by spouse.
United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares at an exercise price of $135.42 on August 6, 2026, then sold the resulting 9,500 common shares in multiple indirect transactions at per-share prices including $512.5000 and $532.3932.
These option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026; 189,410 options remain held by the family trust, alongside direct and other indirect share holdings.